Adalimumab-ryvk Kit
Product Images NDC 51759-310

Product Visual Gallery

This gallery contains 50 technical images submitted to the FDA as part of the official labeling for Adalimumab-ryvk (NDC 51759-310). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Birdi Figure 1 (Avt02 Unbranded Birdi 1)

A line graph showing the percent of ACR20 responders over time in weeks, comparing 40 mg of adalimumab-ryvk every other week (solid line with squares) to placebo (dotted line with circles). The 40 mg treatment group demonstrates a higher and increasing response rate over approximately 48 weeks compared to the placebo group.*

FDA Label Image

Figure 6 (Avt02 Unbranded Birdi 10)

An instructional illustration labeled "Figure E" showing a person washing their hands under a running faucet. Water is depicted flowing over the hands, emphasizing proper handwashing technique.*

FDA Label Image

Figure 7 (Avt02 Unbranded Birdi 11)

An illustration labeled Figure F depicting the recommended injection sites on the human body for Adalimumab-ryvk. Highlighted areas include the abdomen around the navel and the front of the thighs, shown in orange.*

FDA Label Image

Figure 8 (Avt02 Unbranded Birdi 12)

An instructional illustration labeled 'Figure G' showing a hand holding a cloth or wipe, cleaning or rubbing a circular area on a surface. This image appears to be part of a step-by-step instruction guide, likely related to the preparation or use of a medication kit.*

FDA Label Image

Figure 9 (Avt02 Unbranded Birdi 13)

Illustration showing an Adalimumab-ryvk injection pen labeled with 40 mg/0.4 mL dose. The image includes a close-up inset of two windows on the pen, highlighting a liquid indicator, possibly for use or dosage verification. The labeler is Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Figure 10 (Avt02 Unbranded Birdi 14)

An instructional illustration showing a person holding an Adalimumab-ryvk testing device and applying a sample to the test strip. The figure is labeled 'Figure 1' and depicts the step of sample collection or application from a fingertip to the device.*

FDA Label Image

Figure 11 (Avt02 Unbranded Birdi 15)

An instructional illustration showing a hand holding an Adalimumab-ryvk prefilled syringe at a 90-degree angle above an injection site on the skin. The syringe label shows 40 mg/0.8 mL and the Teva logo. This diagram is likely part of usage instructions for administering the drug.*

FDA Label Image

Figure 12 (Avt02 Unbranded Birdi 16)

An instructional illustration showing two steps for using an Adalimumab-ryvk injection pen. The first step (Figure K) shows pressing the device against the skin with a first click, followed by waiting up to 10 seconds. The second step (Figure L) shows a second click during the injection process. The diagram highlights the button and window elements on the device with instructions.*

FDA Label Image

Figure 13 (Avt02 Unbranded Birdi 17)

Instructional illustration showing a hand holding a Teva device vertically with an arrow pointing upward, indicating it should be pulled up. Below, an image of a hand preparing to prick a finger is shown. This figure appears to demonstrate a step in the use of a medical kit, likely for blood sampling or drug administration.*

FDA Label Image

Figure 14 (Avt02 Unbranded Birdi 18)

An instructional illustration labeled 'Figure N' showing a hand disposing of an Adalimumab-ryvk prefilled syringe or injector into a red sharps disposal container with a yellow lid. The image demonstrates proper disposal of the medication delivery device included in the Adalimumab-ryvk kit.*

FDA Label Image

Figure 15 (Avt02 Unbranded Birdi 19)

FDA Label Image

Birdi Figure 2 (Avt02 Unbranded Birdi 2)

A line graph showing the percentage of ASAS 20 response over time in weeks for Adalimumab versus placebo groups. The graph compares response rates in patients receiving Adalimumab (N=208) to placebo (N=107) over a 26-week period, illustrating a higher and sustained response rate in the Adalimumab group compared to placebo.*

FDA Label Image

Birdi 16 (Avt02 Unbranded Birdi 20)

An instructional illustration of a drug delivery device showing labeled parts: Clear Cap, Needle, Orange Needle Sleeve, Inspection Window, and Gray Body Grip Area. The diagram visually explains the components and structure of the device.*

FDA Label Image

Birdi 17 (Avt02 Unbranded Birdi 21)

Illustration labeled Figure A showing a hand inserting a rectangular object into a slot or opening of a vertical device or machine, with an arrow indicating the direction of insertion.*

FDA Label Image

Birdi 18 (Avt02 Unbranded Birdi 22)

An illustration labeled Figure B depicting a clock face with a red shaded area from the 12 to the 6 o'clock position, representing a timeframe of 15 to 30 minutes.*

FDA Label Image

Birdi 19 (Avt02 Unbranded Birdi 23)

An instructional illustration labeled Figure C showing components of a dosing pen or syringe device. The image depicts the device in two views, including a close-up of the dosage end and a label area indicating expiration date and lot number information.*

FDA Label Image

Birdi 20 (Avt02 Unbranded Birdi 24)

An instructional illustration of a medication injection kit for Adalimumab-ryvk, showing a prefilled auto-injector pen with a grey and orange cap, an alcohol swab packet, a cotton ball, and a red sharps disposal container. The image is labeled "Figure D."*

FDA Label Image

Birdi 21 (Avt02 Unbranded Birdi 25)

An instructional illustration labeled Figure E showing hands washing under running water from a faucet. The image likely depicts a hygiene or preparation step for handling the Adalimumab-ryvk kit.*

FDA Label Image

Birdi 22 (Avt02 Unbranded Birdi 26)

An anatomical illustration labeled Figure F showing a human figure with highlighted areas including the abdomen, upper arms, and upper thighs, indicating common injection sites for a medication.*

FDA Label Image

Birdi 23 (Avt02 Unbranded Birdi 27)

An instructional illustration showing a hand holding a cotton ball or pad and wiping a circular area with arrows indicating a circular motion, labeled as Figure G.*

FDA Label Image

Birdi 24 (Avt02 Unbranded Birdi 28)

An illustration showing a kit component of Adalimumab-ryvk by Teva Pharmaceuticals USA, Inc. The image highlights a close-up view of a feature on the device, possibly indicating a window or measurement indicator as part of the product's use instructions or status display.*

FDA Label Image

Birdi 25 (Avt02 Unbranded Birdi 29)

An instructional illustration showing a hand holding an injection device with a clear window, positioned above a small absorbent pad held by another hand. An arrow points downward from the device to the pad, indicating the action of pressing or applying the device onto the pad. The image is labeled 'Figure I.'*

FDA Label Image

Birdi Figure 3 (Avt02 Unbranded Birdi 3)

A line graph comparing treatment failure rates over 20 months for Adalimumab and placebo. The x-axis represents time in months, and the y-axis shows treatment failure rate percentage. Two lines show increasing failure rates over time, with the placebo group exhibiting higher failure rates than the Adalimumab group throughout the study period.*

FDA Label Image

Birdi 26 (Avt02 Unbranded Birdi 30)

Illustration showing the correct way to hold and use a pen-style injector device at a 90-degree angle against the skin for administration. A hand holds the injector vertically while the other hand supports the injection site, demonstrating proper technique for the Adalimumab-ryvk kit.*

FDA Label Image

Birdi 27 (Avt02 Unbranded Birdi 31)

Instructional diagram showing two steps for using a device: Figure K depicts pressing the device against the skin with the first click, accompanied by a clock indicating to wait up to 15 seconds; Figure L depicts pressing for the second click to complete the process.*

FDA Label Image

Birdi 28 (Avt02 Unbranded Birdi 32)

Instructional illustration showing a hand holding a device vertically with an arrow pointing upward, and another image of a hand pinching skin on the forearm, labeled as Figure M. This likely depicts steps for preparing or administering an injection.*

FDA Label Image

Birdi 29 (Avt02 Unbranded Birdi 33)

An illustration showing a hand wearing a black glove disposing of a used syringe or injector device into a red sharps disposal container with a yellow lid, labeled as Figure N. The image demonstrates safe disposal of medical sharps.*

FDA Label Image

Birdi 30 (Avt02 Unbranded Birdi 34)

FDA Label Image

Pfs Image 1 (Avt02 Unbranded Birdi 35)

An illustration showing the parts of a syringe from the Adalimumab-ryvk kit. Labeled components include the Needle Cover, Syringe Body, Finger Grip, and Plunger, detailing the main sections of the injection device.*

FDA Label Image

Pfs Image Figure A (Avt02 Unbranded Birdi 36)

An instructional illustration showing a hand placing a box into a refrigerator compartment, indicated by a black arrow pointing toward the open refrigerator. The image is labeled as Figure A, suggesting it is part of storage or handling instructions for the medication kit.*

FDA Label Image

Pfs Image Figure B (Avt02 Unbranded Birdi 37)

An illustration of a clock face indicating a time range from 15 to 30 minutes, suitable for instructional use such as timing guidance in medication administration or preparation.*

FDA Label Image

Pfs Image 34 (Avt02 Unbranded Birdi 38)

An instructional illustration from the Adalimumab-ryvk kit showing a close-up of a hand holding a prefilled syringe. The image highlights an arrow pointing to inspect the medication inside the syringe, emphasizing checking the solution before use. A partial face with an eye is shown directing attention to the syringe.*

FDA Label Image

Pfs Image 34 (Avt02 Unbranded Birdi 39)

Illustration showing three items: an alcohol swab packet, a cotton ball, and a red sharps disposal container with a yellow lid. These components are typically associated with preparation and disposal in injectable medication administration kits.*

FDA Label Image

Birdi Figure 4 (Avt02 Unbranded Birdi 4)

A line graph showing treatment failure rate percentage over time in months comparing placebo and adalimumab treatments. The graph features two lines: one solid line for placebo and one dashed line for adalimumab, with lower treatment failure rates observed for adalimumab throughout the measured period up to 20 months.*

FDA Label Image

Pfs Image 35 (Avt02 Unbranded Birdi 40)

An instructional illustration showing hands rinsing under running water from a faucet. The image likely demonstrates proper hand washing or cleaning technique prior to medication preparation or administration in a kit.*

FDA Label Image

Pfs Image 37 (Avt02 Unbranded Birdi 41)

Illustration showing recommended injection sites for Adalimumab-ryvk kit on a human body, highlighting areas on the abdomen and front thighs, along with a close-up of hand holding an alcohol swab for skin preparation.*

FDA Label Image

Pfs Image 38 (Avt02 Unbranded Birdi 42)

An instructional illustration showing a hand holding a syringe and another hand removing a cap or protective covering from the syringe needle, indicating preparation for an injection.*

FDA Label Image

Pfs Image 39 (Avt02 Unbranded Birdi 43)

An instructional illustration showing a hand holding a syringe preparing to inject into the forearm of another hand, depicting the administration of an injection, likely related to the Adalimumab-ryvk kit.*

FDA Label Image

Pfs Figure 40 (Avt02 Unbranded Birdi 44)

An instructional illustration showing the proper injection angle of 45 degrees for subcutaneous injection into two sites: the abdomen and the thigh. Each site is depicted with a hand holding a syringe angled and inserted into the skin.*

FDA Label Image

Pfs Image Figure J (Avt02 Unbranded Birdi 45)

An instructional illustration showing a hand holding a syringe or injector device angled toward the skin, with a black arrow pointing down indicating the direction for injection.*

FDA Label Image

Pfs Figure 42 (Avt02 Unbranded Birdi 46)

An instructional illustration showing a hand removing the cap from a syringe before an injection, with an arrow indicating the direction to pull the cap upward from the needle. The illustration depicts the step as part of preparation for using the Adalimumab-ryvk kit.*

FDA Label Image

Pfs Figure L (Avt02 Unbranded Birdi 47)

Illustration showing a hand disposing of a syringe into a red sharps disposal container with a yellow lid, demonstrating safe injection needle disposal.*

FDA Label Image

Pfs Image 44 (Avt02 Unbranded Birdi 48)

An illustration showing a calendar page labeled 'MONTH' with a grid of 35 circles representing days. The last seven circles in the bottom row are shaded differently, possibly indicating a specific week or tracking of time.*

FDA Label Image

40 mg 2 Pk Ai Aw (Avt02 Unbranded Birdi 49)

Packaging label for Adalimumab-ryvk Injection 40 mg/0.4 mL kit. The label indicates it is for subcutaneous use only and contains 2 single-dose autoinjectors. The label shows the NDC number 51759-310-59 and manufacturer Teva Pharmaceuticals USA, Inc. The design includes product identification, usage instructions, and contents detail with a clear layout and color accents.*

FDA Label Image

Birdi Ai 1 Aw (Avt02 Unbranded Birdi 5)

An illustration showing the components of an Adalimumab-ryvk kit injection device. Parts labeled include the Clear Cap, Orange Needle Sleeve, Inspection Window, Plunger Stopper, Gray Body Grip Area, and Needle. The diagram is a side view of the device, highlighting each section for user guidance.*

FDA Label Image

80 mg 1 Ai Aw (Avt02 Unbranded Birdi 50)

Packaging label for Adalimumab-ryvk Injection 80 mg/0.8 mL kit by Teva Pharmaceuticals USA, Inc. Designed for subcutaneous use only, this kit contains one single-dose autoinjector. Label displays dosage strength, route of administration, and includes regulatory and usage information.*

FDA Label Image

Figure 2 Ai (Avt02 Unbranded Birdi 6)

An instructional diagram labeled 'Figure A' showing a hand inserting or pulling out a rectangular object from a vertical slot, possibly part of a device or equipment. The image emphasizes the motion direction with an arrow pointing horizontally.*

FDA Label Image

Figure 3 (Avt02 Unbranded Birdi 7)

An instructional illustration showing a clock with the time range from 15 to 30 minutes highlighted in red, labeled as Figure B. This diagram likely indicates a waiting or processing time interval relevant to the product usage instructions.*

FDA Label Image

Figure 4 (Avt02 Unbranded Birdi 8)

An instructional diagram titled Figure C showing components of the Adalimumab-ryvk kit by Teva Pharmaceuticals USA, Inc. Visible are a prefilled syringe, a small vial or container, a pen device with a display window, and labeling areas indicating expiration date and lot number.*

FDA Label Image

Figure 5 (Avt02 Unbranded Birdi 9)

Illustration depicting components of the Adalimumab-ryvk kit, including a syringe or pen device, an alcohol swab, a cotton ball, and a sharps disposal container. These items are typically used together in medication preparation and administration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.